Gossamer Bio Announces $212 Million Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- Wall St futures mixed as tech wobbles again, Tesla gains
- Oil eases but heads for small weekly gain as investors focus on Middle East supply
- U.S. producer prices rise by 1.3% month-on-month in September
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Vertiv shares fall on analyst downgrades and options bets
- European stocks rise as markets stabilise, dollar set for weekly loss
- S&P 500 ends higher as traders shift from AI to healthcare
- Rocket Lab USA (RKLB) Reiterated at Overweight by Cantor Fitzgerald as Neutron Launch Moved to Next Year
- Caterpillar names Derrick York to lead Resource Industries
Evercore ISI Downgrades Gossamer Bio Inc. (GOSS) to In Line, 'Long Path Ahead'
July 20, 2023 11:37 AM EDTEvercore ISI analyst Josh Schimmer downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to In Line with a price target of $4.00 (from $6.00).
The analyst comments "GOSS reported an initial look at the P2 OLE data for seralutinib in PAH, along with a large financing... More



